Status:
TERMINATED
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Carcinoma, Transitional Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tra...
Eligibility Criteria
Inclusion
- Transitional cell carcinoma
- Histologically-proven
- Locally advanced unresectable or metastatic
- With at least one measurable target
- Informed consent signed
Exclusion
- Previous chemotherapy
- Previous radiotherapy
- Performance status \>=2
- Peripheral neuropathy \>=1
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00127595
Start Date
January 1 2002
End Date
April 1 2005
Last Update
August 24 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Gustave Roussy
Villejuif, France, 94805